Archer Materials Limited (AU:AXE) has released an update.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Archer Materials is making strides in advancing its Biochip technology, focusing on improving the accuracy of graphene field effect transistor sensors for blood potassium testing, crucial for chronic kidney disease diagnosis. By refining sensor operations and design, Archer aims to enhance test precision significantly, with recent experiments showing a tenfold improvement in measurement repeatability. This development could revolutionize home diagnostics and patient outcomes by enabling more accurate and accessible chronic kidney disease testing.
For further insights into AU:AXE stock, check out TipRanks’ Stock Analysis page.